Cargando…
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum(TM)
BACKGROUND: Lenabasum is a cannabinoid type 2 receptor (CB2R) reverse agonist that demonstrates anti-inflammatory effects in vivo and in vitro in dermatomyositis (DM) and is currently being investigated for therapeutic potential. The purpose of our study is to investigate CB2R distribution as well a...
Autores principales: | Maddukuri, Spandana, Patel, Jay, Diaz, De Anna, Chen, Kristen L., Wysocka, Maria, Bax, Christina, Li, Yubin, Ravishankar, Adarsh, Grinnell, Madison, Zeidi, Majid, Reddy, Nithin, Concha, Josef Symon S., Bashir, Muhammad M., Okawa, Joyce, White, Barbara, Werth, Victoria P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725283/ https://www.ncbi.nlm.nih.gov/pubmed/34983619 http://dx.doi.org/10.1186/s13075-021-02665-x |
Ejemplares similares
-
Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of Lenabasum(TM)
por: Maddukuri, Spandana, et al.
Publicado: (2022) -
Environmental triggers of dermatomyositis: a narrative review
por: Bax, Christina E., et al.
Publicado: (2021) -
Herbal supplement Spirulina stimulates inflammatory cytokine production in patients with dermatomyositis in vitro
por: Bax, Christina E., et al.
Publicado: (2023) -
Plasma-derived DNA containing-extracellular vesicles induce STING-mediated proinflammatory responses in dermatomyositis
por: Li, Yubin, et al.
Publicado: (2021) -
278 Photo validation study using cutaneous dermatomyositis disease area and severity index in dermatomyositis patients
por: Grinnell, M., et al.
Publicado: (2022)